Abstract 132P
Background
To perform competing risk analysis and evaluate cancer- and noncancer-specific mortality in patients with gastric cancer after radical surgery.
Methods
A total of 5051 patients from our department (as training set) and a total of 7123 patients from the Surveillance, Epidemiology, and End Results (SEER) database (as validation set) were enrolled in the study. The cumulative incidence of cancer and noncancer-specific mortality was determined by univariate and multivariate competing risk analysis.
Results
The five-year cancer- and noncancer-specific cumulative incidence of death (CID) in the training set were 36.9% and 2.5%, respectively, which were significantly lower than that in the validation set (48.2% and 8.6%, respectively). Multivariable analysis showed that age, tumor site, tumor size and pTNM stage were independent predictors of gastric cancer-specific mortality and overall survival, whereas age was an independent predictor of gastric noncancer-specific mortality. Noncancer–specific CID surpassed cancer-specific CID for pTNM stage I patients after approximately 8 years of surgery, but never for stage II and III patients. Moreover, for stage I patients, the time point when noncancer–specific CID surpassed cancer-specific CID become earlier as age increasing, with only 3.5 years after surgery for patients more than 74 years of age.
Conclusions
Age is an independent predictor of gastric cancer- and noncancer specific mortality and overall survival for patients after radical surgery. For patients with stage I gastric cancer, noncancer-specific mortality is a significant competing event, with an increasing impact as age increases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session